Q3 EPS Estimate for Akero Therapeutics Increased by Analyst

Akero Therapeutics, Inc. (NASDAQ:AKRO) – Equities researchers at Lifesci Capital lifted their Q3 2025 earnings per share estimates for shares of Akero Therapeutics in a research report issued to clients and investors on Monday, August 11th. Lifesci Capital analyst R. Katkhuda now anticipates that the company will post earnings of ($0.90) per share for the quarter, up from their prior estimate of ($0.95). The consensus estimate for Akero Therapeutics’ current full-year earnings is ($3.99) per share. Lifesci Capital also issued estimates for Akero Therapeutics’ Q4 2025 earnings at ($0.93) EPS and FY2025 earnings at ($3.59) EPS.

A number of other equities analysts also recently weighed in on the company. TD Cowen assumed coverage on Akero Therapeutics in a research note on Monday, August 4th. They issued a “buy” rating and a $76.00 target price on the stock. Cowen assumed coverage on Akero Therapeutics in a research note on Monday, August 4th. They issued a “buy” rating on the stock. Bank of America boosted their target price on Akero Therapeutics from $63.00 to $64.00 and gave the stock a “buy” rating in a research note on Tuesday, May 27th. Finally, Citigroup cut their target price on Akero Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Tuesday, May 13th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Akero Therapeutics has an average rating of “Buy” and a consensus target price of $81.57.

Akero Therapeutics Price Performance

Shares of NASDAQ AKRO opened at $50.09 on Wednesday. Akero Therapeutics has a twelve month low of $21.34 and a twelve month high of $58.40. The stock’s 50 day moving average price is $52.05 and its 200-day moving average price is $47.34. The company has a market capitalization of $4.01 billion, a PE ratio of -25.05 and a beta of -0.28. The company has a quick ratio of 16.80, a current ratio of 12.66 and a debt-to-equity ratio of 0.02.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings data on Friday, August 8th. The company reported ($0.86) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.11. During the same period in the prior year, the business earned ($0.81) EPS.

Insider Transactions at Akero Therapeutics

In other Akero Therapeutics news, COO Jonathan Young sold 12,500 shares of the stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $47.79, for a total transaction of $597,375.00. Following the completion of the transaction, the chief operating officer directly owned 197,484 shares of the company’s stock, valued at approximately $9,437,760.36. This represents a 5.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Catriona Yale sold 10,000 shares of the stock in a transaction on Monday, June 16th. The shares were sold at an average price of $54.23, for a total value of $542,300.00. Following the transaction, the insider directly owned 92,231 shares of the company’s stock, valued at approximately $5,001,687.13. This trade represents a 9.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 230,406 shares of company stock valued at $12,013,920 in the last three months. 7.07% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Akero Therapeutics

Several institutional investors have recently made changes to their positions in AKRO. Wells Fargo & Company MN lifted its position in shares of Akero Therapeutics by 14.0% during the fourth quarter. Wells Fargo & Company MN now owns 61,867 shares of the company’s stock worth $1,721,000 after acquiring an additional 7,587 shares in the last quarter. Invesco Ltd. lifted its position in shares of Akero Therapeutics by 27.3% during the fourth quarter. Invesco Ltd. now owns 98,463 shares of the company’s stock worth $2,739,000 after acquiring an additional 21,086 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Akero Therapeutics during the fourth quarter worth $579,000. Sterling Capital Management LLC lifted its position in shares of Akero Therapeutics by 764.3% during the fourth quarter. Sterling Capital Management LLC now owns 1,789 shares of the company’s stock worth $50,000 after acquiring an additional 1,582 shares in the last quarter. Finally, Summit Investment Advisors Inc. lifted its position in shares of Akero Therapeutics by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company’s stock worth $197,000 after acquiring an additional 450 shares in the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.